Search Within

Rona Denit Yaeger

Formats
  1. Meeting Abstract (164)
  2. Journal Article (140)
  3. Review (7)
  4. Editorial (6)
  5. Research Letter (4)
  6. Book Section (1)
  7. Correspondence (1)
  8. Guidelines (1)
Groups
  1. Department of Medicine (324)
  2. Gastrointestinal Oncology Service (324)
  3. Solid Tumor Oncology Division (324)
  4. Center for Pancreatic Cancer Research (135)
  5. GSK Faculty (133)
  6. Department of Pathology and Laboratory Medicine (124)

More Groups

People
  1. Andrea Cercek Hanjis (94)
  2. Leonard Saltz (80)
  3. Jinru Shia (75)
  4. Martin Weiser (64)
  5. Zsofia Stadler (61)
  6. Julio Garcia Aguilar (60)

More People

Years
  1. 2025 (24)
  2. 2024 (41)
  3. 2023 (37)
  4. 2022 (39)
  5. 2021 (36)
  6. 2020 (28)

More Years

Publications
  1. Journal of Clinical Oncology (101)
  2. Annals of Oncology (36)
  3. Clinical Cancer Research (17)
  4. Cancer Research (15)
  5. Cancer Discovery (14)
  6. Nature Medicine (9)

More Publications

Publishers
  1. American Society of Clinical Oncology (111)
  2. American Association for Cancer Research (50)
  3. Oxford University Press (47)
  4. Nature Publishing Group (26)
  5. Elsevier Inc. (19)
  6. Springer (9)

More Publishers

Results (324)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer
    Journal Article

    Elez, E.; Yoshino, T.; Shen, L.; Lonardi, S.; Van Cutsem, E.; Eng, C.; Kim, T. W.; Wasan, H. S.; Desai, J.; Ciardiello, F.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Direct inhibition of RAS reveals the features of oncogenic signaling driven by RAS G12 and Q61 mutations
    Journal Article

    Marasco, M.; Kumar, D.; Garcia Borrego, S.; Seale, T.; Maddalena, G.; Mezzadra, R.; Belanger, K.; Cole, S.; Perez, B.; Luan, W.; more...
    Cancer Discovery (2025)

    Fulltext@MSK | Save
  • First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses
    Meeting Abstract

    Elez, E.; Yoshino, T.; Shen, L.; Lonardi, S.; Van Cutsem, E.; Eng, C.; Kim, T. W.; Wasan, H. S.; Desai, J.; Ciardiello, F.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers
    Meeting Abstract

    Schreck, K. C.; De La Fuente, M. I.; Rine, J.; Kline, I.; Shephard, S. P.; Ahnert, J. R.; Sherman, E. J.; Yaeger, R.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1/2 study of FOG-001, a first-in-class direct β-catenin: TCF inhibitor, in patients with colorectal cancer (CRC) and other locally advanced or metastatic solid tumors
    Meeting Abstract

    Papadopoulos, K. P.; Cecchini, M.; Khushman, M. M.; Pelster, M.; Rodon Ahnert, J.; Kummar, S.; Yaeger, R.; Sharma, S.; Wells, A.; Garofalo, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A plain language summary of the molecular changes in the tumors of people with BRAF V600E–mutant colorectal cancer in the BEACON study
    Editorial

    Kopetz, S.; Murphy, D. A.; Pu, J.; Ciardiello, F.; Desai, J.; Van Cutsem, E.; Wasan, H. S.; Yoshino, T.; Saffari, H.; Zhang, X.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: A plain language summary
    Editorial

    Kopetz, S.; Yoshino, T.; Van Cutsem, E.; Eng, C.; Kim, T. W.; Wasan, H. S.; Desai, J.; Ciardiello, F.; Yaeger, R.; Maughan, T. S.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Surrogate end points in oncology: Aligning drug development incentives and patient needs
    Correspondence

    Vogel, M.; Yaeger, R.; Stewart, D. J.; Subbiah, V.; David, F. S.
    Nature Reviews Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Nonoperative management of mismatch repair-deficient tumors
    Journal Article

    Cercek, A.; Foote, M. B.; Rousseau, B.; Smith, J. J.; Shia, J.; Sinopoli, J.; Weiss, J.; Lumish, M.; Temple, L.; Patel, M.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Tumorigenesis driven by BRAF(V600E) requires secondary mutations that overcome its feedback inhibition of RAC1 and migration
    Journal Article

    Gadal, S.; Boyer, J. A.; Roy, S. F.; Outmezguine, N. A.; Sharma, M.; Li, H.; Fan, N.; Chan, E.; Romin, Y.; Barlas, A.; more...
    Cancer Research (2025)

    Fulltext@MSK | Save